Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

NCT06331169 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Anlotinib
DRUG: Trastuzumab deruxtecan

Sponsor

Fudan University